For example, combining tirzepatide with other GLP-1 receptor agonists is generally not recommended, as they have similar mechanisms of action and could lead to overlapping side effects
In a recently completed phase 2 trial (abstract data), 46 weeks of survodutide once weekly (0.6 to 4.8 mg) resulted in a dose-dependent mean WL up to 18.7% vs
And without the continued downward trajectory that motivated continued use, exploring alternatives with different mechanisms becomes an appealing strategy to break through stalled progress
Liraglutide (Saxenda, Victoza) Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management
GLP-1 medications help with weight loss by enhancing the function of this natural hormone
[DOI] [PubMed] [Google Scholar] 13.Ard J., Cannon A., Lewis C.E., Lofton H., Vang Skjth T., Stevenin B., Pi-Sunyer X